<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00586716</url>
  </required_header>
  <id_info>
    <org_study_id>54298</org_study_id>
    <nct_id>NCT00586716</nct_id>
  </id_info>
  <brief_title>Intravenous Immune Globulin (IVIG) Treatment Protocol in Kidney Transplant Patients</brief_title>
  <official_title>IVIG Treatment for Live-donor Renal Transplant Patients With a Positive Crossmatch and in Patients With High PRA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the clinical and laboratory observations of IVIG therapy
      in the highly sensitized patient. We will study the effects of patients treated with IVIG or
      Cytogam in combination with plasmaphoresis to modulate the immune response in highly
      sensitized patients. The goal is to convert a positive crossmatch to a compatible crossmatch
      that would allow living related transplant to take place or to shorten time on the transplant
      waiting list.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to test the clinical and laboratory observations of IVIG therapy
      in the highly sensitized patient. We will study the effects of patients treated with IVIG or
      Cytogam in combination with plasmaphoresis to modulate the immune response in highly
      sensitized patients. There are two arms in the study, one in which IVIG is administered to
      patients who have living donors with positive crossmatch results, and another in which
      intravenous immune globulin is administered to patients with no living donor and have a PRA
      greater than 30% for 3 consecutive months and a crossmatch with a cadaveric donor while on
      kidney transplant waiting list. The goal is to convert a positive crossmatch to a compatible
      crossmatch that would allow living related transplant to take place or to shorten time on the
      transplant waiting list.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient recruitment
  </why_stopped>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Elimination of Donor Specific Antibodies</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative B and T Cell Crossmatch</measure>
    <time_frame>1year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Group 1 intravenous immune globulin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intravenous immunoglobulin for: patients who do not have a living donor, have a PRA greater than 30% for 3 consecutive months, and have one positive crossmatch with a cadaveric donor while on kidney transplant waiting list</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 intravenous immune globulin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intravenous immune globulin for patients who have living donors with positive crossmatch results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous immune globulin</intervention_name>
    <description>0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments</description>
    <arm_group_label>Group 1 intravenous immune globulin</arm_group_label>
    <arm_group_label>Group 2 intravenous immune globulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  12 years of age or older

          -  diagnosed with end stage renal disease

          -  currently receiving either hemodialysis or peritoneal dialysis

          -  active on the kidney or kidney/pancreas transplant list

          -  medical clearance of the kidney donor if live related transplant

          -  elevated panel reactive antibody (PRA) greater that 30% for 3 consecutive monthly
             tests and one positive crossmatch with a cadaveric donor while on the transplant
             waiting list

        Exclusion Criteria:

          -  received IVIG within 6 months prior to enrollment

          -  HIV positive

          -  Positive Hepatitis Be-antigen and/or hepatitis B viral DNA

          -  Selective IgA deficiency or known antibodies to IgA

          -  Allergy to human immune globulin

          -  Pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Okechukwu Ojogho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda Universtiy Adventist Health Sciences Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2008</study_first_posted>
  <results_first_submitted>May 29, 2014</results_first_submitted>
  <results_first_submitted_qc>April 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 6, 2016</results_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 Intravenous Immune Globulin no Living Donor</title>
          <description>Patients who do not have a living donor, have a PRA greater than 30% for 3 consecutive months, and have one positive crossmatch with a cadaveric donor while on kidney transplant waiting list
intravenous immune globulins : 0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments</description>
        </group>
        <group group_id="P2">
          <title>Group 2 Intravenous Immune Globulin With Living Donor</title>
          <description>Patients who have living donors with positive crossmatch results.
intravenous immune globulins : 0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IVIG no Living Donor</title>
          <description>Intravenous immunoglobulin for: patients who do not have a living donor, have a PRA greater than 30% for 3 consecutive months, and have one positive crossmatch with a cadaveric donor while on kidney transplant waiting list</description>
        </group>
        <group group_id="B2">
          <title>IVIG With Living Donor</title>
          <description>Intravenous immune globulin for patients who have living donors with positive crossmatch results.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Elimination of Donor Specific Antibodies</title>
        <time_frame>1 year</time_frame>
        <population>Study was terminated and no data for the outcome was collected/analyzed because it could not be located.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Immune Globulin</title>
            <description>Intravenous immune globulin for patients who have living donors with positive crossmatch results</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination of Donor Specific Antibodies</title>
          <population>Study was terminated and no data for the outcome was collected/analyzed because it could not be located.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Negative B and T Cell Crossmatch</title>
        <time_frame>1year</time_frame>
        <population>Study was terminated and no data for the outcome was collected/analyzed because it could not be located.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Intravenous Immune Globulin</title>
            <description>Intravenous immunoglobulin for: patients who do not have a living donor, have a PRA greater than 30% for 3 consecutive months, and have one positive crossmatch with a cadaveric donor while on kidney transplant waiting list
intravenous immune globulin: 0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Intravenous Immune Globulin</title>
            <description>Intravenous immune globulin for patients who have living donors with positive crossmatch results.
intravenous immune globulin: 0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Negative B and T Cell Crossmatch</title>
          <population>Study was terminated and no data for the outcome was collected/analyzed because it could not be located.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and non-serious adverse events were not collected/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 Intravenous Immune Globulin</title>
          <description>Group 1 with Intravenous immune globulin with no living donor</description>
        </group>
        <group group_id="E2">
          <title>Group 2 Intravenous Immune Globulin</title>
          <description>Group 2 intravenous immune globulin WITH living donor</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation to this study is early termination leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Pedro Baron</name_or_title>
      <organization>Loma Linda University Medical Center</organization>
      <phone>909-558-6792</phone>
      <email>PBaron@llu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

